RE: Good rise, but justified6 Aug 2019 15:48
Potentially yes, but this is what they say on their website. Basically we are still trading below our NAV, and nothing at all is being taken into account for the bio business. So even if an RNS was issued, hopefully it would reiterate the value disconnect (rather than say "we know of no reason for the rise...")
"Ovoca is a strongly capitalized business. As at 31 December 2017, the Company had net assets of €22.4 million, which included cash and cash equivalents of €5.5 million and available for sale financial assets of €15.9 million. Ovoca has no current outstanding debt. In recent years, Ovoca’s share price has continued to trade at what the Existing Directors believe to be a significant discount to its net asset value per Ordinary Share. At 31 December 2017, such discount was approximately 68 per cent."